Breaking News

Santa Ana Bio Emerges from Stealth with $168M in Funding

The company has multiple differentiated biologics tracking towards clinical entry in 2025.

Author Image

By: Charlie Sternberg

Associate Editor

Santa Ana Bio, a precision immunology company developing targeted therapies for patients with autoimmune and inflammatory diseases, has emerged from stealth with $168 million in combined Series A and B funding.   Founding investor Versant Ventures led the Series A round and was joined by TPG’s Life Science Innovations fund and GV. The $125 million Series B round was led by GV, with participation from all existing investors as well as new investors Access Biotechnology, Andreessen Horowitz (a16...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters